Authors: Birgit Sawitzki, Paul N. Harden, Petra Reinke, Aurélie Moreau, James A. Hutchinson, David Game, Qizhi Tang, Eva C. Guinan, Manuela Battaglia, William J. Burlingham, Ian S.D. Roberts, Mathias Streitz, Régis Josien, Carsten A. Böger, Cristiano Scottà, James F. Markmann, Joanna Hester, Karsten Juerchott, Cécile Braudeau, Ben James, Laura Contreras-Ruiz, Jeroen B. van der Net, Tobias Bergler, Rossana Caldara, William Petchey, Matthias Edinger, Nathalie Dupas, Michael Kapinsky, Ingrid Mutzbauer, Natalie M Otto, Robert Öllinger, Maria P. Hernandez-Fuentes, Fadi Issa, Norbert Ahrens, Christoph Meyenberg, Sandra Karitzky, Ulrich Kunzendorf, Stuart J. Knechtle, Josep M. Grinyó, Peter J. Morris, Leslie Brent, A. Bushell, Laurence A. Turka, Jeffrey A. Bluestone, Robert I. Lechler, Hans J. Schlitt, M. C. Cuturi, Stephan Schlickeiser, P Friend, Tewfik Miloud, Alexander Scheffold, Antonio Secchi, Kerry Crisalli, Sang-Mo Kang, Rachel Hilton, Bernhard Banas, Gilles Blancho, Hans-Dieter Volk, Giovanna Lombardi, Kathryn J. Wood, Edward K. Geissler

Venue: The Lancet

Type: Publication

Abstract: Background: Use of cell-based medicinal products (CBMPs) represents a state-of-the-art approach for reducing general immunosuppression in organ transplantation. We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment. Methods: The ONE Study consisted of seven investigator-led, single-arm trials done internationally at eight hospitals in France, Germany, Italy, the UK, and the USA (60 week follow-up). Included patients were living... (read more)

DOI: 10.1053/j.ajkd.2020.07.006 (Found 2 versions)